PROSCA/BLADDR 2023 | Positive surgical margins after RC for MIBC: what’s next?

Paul Sargos, MD, Institut Bergonié in Bordeaux, France, explores the topic of positive surgical margins after radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) and the potential role of adjuvant therapy. Noting that adjuvant immunotherapy trials often exclude patients with positive margins, he suggests considering adjuvant radiotherapy as a viable option. Citing Phase III data demonstrating excellent outcomes in locoregional relapse and metastatic relapse-free survival, along with Phase II contemporary data supporting its safety, Dr Sargos sees adjuvant radiotherapy as a promising approach. Ongoing trials and meta-analyses further contribute to the evaluation of this strategy. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP), protected by copyright laws and treaties globally, with all rights reserved.